G1 Therapeutics (GTHX) Gets a Buy Rating from Needham
In a report released today, Chad Messer from Needham reiterated a Buy rating on G1 Therapeutics (GTHX), with a price target of $74.00. The company’s shares closed last Monday at $15.30.
According to TipRanks.com, Messer is a 5-star analyst with an average return of 9.8% and a 47.0% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Aeglea Biotherapeutics, and Ionis Pharmaceuticals.
Currently, the analyst consensus on G1 Therapeutics is a Strong Buy with an average price target of $56.80, a 278.7% upside from current levels. In a report issued on July 23, H.C. Wainwright also maintained a Buy rating on the stock with a $82.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $41.80 and a one-year low of $8.80. Currently, G1 Therapeutics has an average volume of 553.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.